NICE approves Taxol for ovarian cancer
Kmietowicz, Z.
Bmj 320(7245): 1293
2000
ISSN/ISBN: 0959-8138 PMID: 10807610 Document Number: 523020
Document emailed within 1 workday
Related Documents
White 2000: NICE approves taxanes for breast cancer Bmj 320(7251): 1688a1996: Chemotherapy of ovarian and breast cancer with Taxol Deutsche Medizinische Wochenschrift 121(50 Suppl): 1-12
1992: Taxol improves outlook for lung, breast, and ovarian cancer Oncology 6(8): 16
Ozols, R.F. 2000: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer Seminars in Oncology 27(3 Suppl 7: 3-7
Sen, S.; Zocchetti, A.; Beccaglia, P.; Balconi, G.; Erba, E.; D'Incalci, M. 1994: Heterogeneous interaction of interferon-beta and taxol in human ovarian cancer cells in vitro European Journal of Cancer 30a(6): 892-893
Ezcurdia, L.; Jovtis, S.L.; Mickiewicz, E.; Temperley, G.; Rondinón, M.; Blajman, C.; Cóppola, F.S.; Lewi, D.; Cazap, E.; Breier, S.; Fasce, H.; Fein, L.; Polera, J.; Triguboff, E.; Uranga, G.; Pasccón, G.; Luchina, A.M.; Martínez, C.A.; Politi, P.M.; Rubio, G.; Alvarez, A.M. 1997: Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group Seminars in Oncology 24(5 Suppl. 15): S15
Frankel, A.; Buckman, R.; Kerbel, R.S. 1997: Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids Cancer Research 57(12): 2388-2393
Bhat, N.; Perera, P.Y.; Carboni, J.M.; Blanco, J.; Golenbock, D.T.; Mayadas, T.N.; Vogel, S.N. 1999: Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression Journal of Immunology 162(12): 7335-7342
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210
Hartge, P.; Hayes, R.; Reding, D.; Sherman, M.E.; Prorok, P.; Schiffman, M.; Buys, S. 2000: Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial American Journal of Obstetrics and Gynecology 183(5): 1232-1237
Muhlradt, P.F.; Sasse, F. 1997: Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity Cancer Research 57(16): 3344-3346
Fletcher, P. 2000: Do NICE and CHI have no interest in safety? Opinion of the book NICE, CHI and the NHS reforms. Enabling excellence or imposing control? Adverse Drug Reactions and Toxicological Reviews 19(3): 167-176
Rawlins, M.D. 2001: The failings of NICE. Reply from chairman of NICE Bmj 322(7284): 489
Suzuki, M.; Sekiguchi, I.; Tamada, T.; Sakurabayashi, I.; Kawai, T. 1985: Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors Rinsho Byori. Japanese Journal of Clinical Pathology 33(2): 173-177
Rose, P.G.; Hunter, R.E. 1994: Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report Journal of Reproductive Medicine 39(11): 908-910
Tanaka, K. 1989: Ovarian cancer--assessment of methods for cytogenetic analysis and chromosome aberrations found in ovarian cancer Rinsho Byori. Japanese Journal of Clinical Pathology Spec no 80: 268-280
Vanhaelen, M.H. 1992: Taxol and related diterpenoids of Taxus sp.: important acquisitions in the treatment of cancer Journal de Pharmacie de Belgique 47(5): 417-424
Plasswilm, L.; Kirschner, M.; Sauer, R. 1996: Concurrent Taxol and split-course accelerated radiotherapy for advanced head and neck cancer Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 172(10): 573-579
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Chou, Y-Ching.; Chen, Y-Jen.; Lai, C-Ru.; Wang, P-Hui.; Hsin-Chan; Yuan, C-Chung. 2006: Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis European Journal of Obstetrics Gynecology and Reproductive Biology 124(1): 101-105